By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Coherus Biosciences 

201 Redwood Shores Parkway
Suite 200
Redwood City  California  94065  U.S.A.
Phone: 800-794-5434 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen (AMGN)'s Neulasta 6/12/2017 5:54:54 AM
Coherus Prevails In ‘135 IPR Decision 5/17/2017 11:12:36 AM
Coherus Reports First Quarter 2017 Corporate Highlights And Financial Results 5/9/2017 10:52:28 AM
Coherus Completes Patent Dance Exchange With Amgen (AMGN) For Neulasta Biosimilar 4/25/2017 9:49:34 AM
Coherus To Report First Quarter 2017 Financial Results On May 8th 4/24/2017 11:06:46 AM
Amgen (AMGN) Files Trade Secret Action Against Bay Area's Coherus 3/6/2017 5:34:58 AM
Coherus Announces Proposed Public Offering Of Common Stock 2/8/2017 7:42:07 AM
Coherus And Baxalta (BXLT) Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoint In Phase III Rheumatoid Arthritis Clinical Study (Rapsody) 1/11/2016 8:12:10 AM
Coherus To Present At Jefferies Autumn 2015 Global Healthcare Conference On November 18 11/10/2015 11:39:25 AM
Coherus And Baxalta (BXLT) Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoints in Phase 3 Psoriasis Clinical Study (RaPsODY) 11/10/2015 9:57:10 AM
12345
//-->